Developer docs
API playgroundTry for free, no card

Search company profiles

Digestive Care

Full company profile

uuid000tdiv

Namestring
Digestive Care
Legal namestring
Digestive Care, Inc.
Company typeenum
Private
Founded yearint
1990
Descriptiontext

Digestive Care, Inc. is a private specialty pharmaceutical company founded in 1990 by Ranvir Singh and headquartered in Bethlehem, Pennsylvania. The company develops, manufactures, and markets PERTZYE (pancrelipase), a prescription Pancreatic Enzyme Replacement Therapy (PERT) indicated for the treatment of Exocrine Pancreatic Insufficiency (EPI) in adult and pediatric patients. EPI is a condition in which the pancreas does not produce sufficient digestive enzymes, and is commonly associated with cystic fibrosis, chronic pancreatitis, pancreatic cancer, and post-pancreatic surgery. PERTZYE is differentiated by its proprietary Bicarbonate-Buffered Enteric-Coated Microspheres technology, which protects the digestive enzymes from gastric acid and delivers them to the small intestine. The product line spans four lipase unit strengths (4,000, 8,000, 16,000, and 24,000) plus a G-tube formulation for patients unable to swallow capsules, supporting individualized dosing across a broad patient population.

Digestive Care operates a sales-led, prescription-based go-to-market in which healthcare providers (gastroenterologists, pulmonologists treating cystic fibrosis, and related specialists) prescribe PERTZYE and patients fill prescriptions through retail and specialty pharmacies. Distribution is US-only, with PERTZYE manufactured in the United States. The company operates between 11 and 50 employees and supports its franchise with an extensive suite of patient access and adherence programs, including a Co-Pay Card, EPI Nutrition Program, First Start Program, Infant Starter Program, My EPI Plan, Pertzye Care, and an Uninsured Patient Assistance Program.

The company remains privately held with no disclosed parent company, institutional investors, or funding rounds. Commercial activity is concentrated entirely on the PERTZYE franchise; no additional pipeline assets, partnerships, acquisitions, or geographic expansion initiatives are identified in the available data. Pricing is not publicly disclosed and is described as determined by insurance coverage, pharmacy benefit managers, and patient assistance programs.

Short descriptiontext

Digestive Care is a private US specialty pharmaceutical company that develops and manufactures PERTZYE, the only FDA-approved pancreatic enzyme replacement therapy containing bicarbonate-buffered enteric-coated microspheres, for adult and pediatric patients with exocrine pancreatic insufficiency (EPI).

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBethlehem, United States
HQ citystring
Bethlehem
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
pancreatic enzyme therapy, exocrine pancreatic insufficiency, prescription pharmaceuticals, gastroenterology drugs, cystic fibrosis treatment
Industry2 codes
PRIMARYHLAIACAE
Gastroenterology Specialty Pharmaceuticals
SECONDARYHLAKAEAG
Pancreaticobiliary Disorders
Product category
Prescription Pharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Prescription Pharmaceutical Sales
TypeOthers
Description

Digestive Care generates revenue through the sale of prescription pancreatic enzyme replacement therapy (PERT) products. Pertzye is available in multiple dosage strengths (4000, 8000, 16000, and 24000 lipase units) and as a G-tube formulation for patients who cannot swallow capsules.

pertzye.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1PERTZYE
Description

Pancreatic Enzyme Replacement Therapy (PERT) containing Bicarbonate-Buffered Enteric-Coated Microspheres, available in 4000, 8000, 16000, and 24000 lipase unit capsules

pertzye.com
Core offering1 text field

Digestive Care manufactures and markets PERTZYE (pancrelipase), a prescription pancreatic enzyme replacement therapy (PERT) for treating exocrine pancreatic insufficiency (EPI) in adult and pediatric patients. The product line is available in four capsule strengths (4000, 8000, 16000, and 24000 lipase units) plus a G-tube formulation for patients with swallowing difficulties, all built on proprietary Bicarbonate-Buffered Enteric-Coated Microsphere technology.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Digestive Care offers a unified portfolio of prescription pancreatic enzyme replacement therapies centered on PERTZYE, the only PERT containing Bicarbonate-Buffered Enteric-Coated Microspheres. The product line consists of five dosage strengths (4000, 8000, 16000, and 24000 lipase units) plus a G-tube formulation, all designed to treat exocrine pancreatic insufficiency (EPI) in adults and children. The various lipase unit strengths allow for individualized dosing based on patient needs, while the G-tube variant addresses administration challenges for patients with swallowing difficulties. The portfolio is supported by patient assistance programs including Co-Pay Card, EPI Nutrition Program, First Start Program, Infant Starter Program, My EPI Plan, Pertzye Care, and Uninsured Patient Assistance Program.

Product and service5 records
1PERTZYE 4000
CategoryPancreatic Enzyme Replacement Therapy
Description

Pancreatic Enzyme Replacement Therapy (PERT) capsules containing 4000 lipase units, indicated for treatment of exocrine pancreatic insufficiency (EPI) in adult and pediatric patients.

2PERTZYE 8000
3PERTZYE 16000
4PERTZYE 24000
5PERTZYE G-tube
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

Nestlé Health Science markets Zenpep, one of the leading US PERT products with multiple dosage strengths. Directly competes with PERTZYE in the same pancreatic enzyme replacement category for EPI patients across adult and pediatric populations.

TypeBroad incumbent
Description

Takeda operates a broad gastroenterology and rare disease portfolio including enzyme and GI therapies. While not a direct US PERT competitor, operates in the same gastroenterology specialty prescriber channel where Digestive Care competes for attention and formulary access.

TypeDirect peer
Description

Chiesi was the original developer of the PERTZYE formulation (originally branded PANCRECARB) and markets competing pancreatic enzyme products internationally. Has deep technical familiarity with the bicarbonate-buffered microsphere technology underlying Digestive Care's product.

TypeDirect peer
Description

ANI Pharmaceuticals markets generic and branded pancrelipase products including competing PERT formulations. Directly competes in the same EPI category with similar capsule-based delivery across multiple dosage strengths.

TypeDirect peer
Description

AbbVie markets Creon, the market-leading pancreatic enzyme replacement therapy with majority share in the US PERT market. Directly competes with PERTZYE across the same gastroenterology, pulmonology, and pancreatic insufficiency prescriber base.

TypeDirect peer
Description

Vivus markets Pancreaze, a competing pancreatic enzyme replacement therapy capsule product. Directly competes with PERTZYE across the same EPI prescriber channels with similar capsule-based delivery and multiple dosage strengths.

TypeEmerging player
Description

Alcresta specializes in pancreatic enzyme products for pediatric and tube-fed patients including those with cystic fibrosis. Adjacent PERT competitor focused on specialized delivery formats that overlap with PERTZYE's G-tube and pediatric positioning.

TypeBroad incumbent
Description

Salix Pharmaceuticals is Bausch Health's gastroenterology specialty division with a broad GI product portfolio including pancreatic enzymes (historically Viokace). Operates in the same gastroenterology prescriber channel as Digestive Care with overlapping physician relationships.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Digestive Care

Prescription Pharmaceuticalsdigestivecare.com

Digestive Care is a private US specialty pharmaceutical company that develops and manufactures PERTZYE, the only FDA-approved pancreatic enzyme replacement therapy containing bicarbonate-buffered enteric-coated microspheres, for adult and pediatric patients with exocrine pancreatic insufficiency (EPI).

What Digestive Care does

Digestive Care, Inc. is a private specialty pharmaceutical company founded in 1990 by Ranvir Singh and headquartered in Bethlehem, Pennsylvania. The company develops, manufactures, and markets PERTZYE (pancrelipase), a prescription Pancreatic Enzyme Replacement Therapy (PERT) indicated for the treatment of Exocrine Pancreatic Insufficiency (EPI) in adult and pediatric patients. EPI is a condition in which the pancreas does not produce sufficient digestive enzymes, and is commonly associated with cystic fibrosis, chronic pancreatitis, pancreatic cancer, and post-pancreatic surgery. PERTZYE is differentiated by its proprietary Bicarbonate-Buffered Enteric-Coated Microspheres technology, which protects the digestive enzymes from gastric acid and delivers them to the small intestine. The product line spans four lipase unit strengths (4,000, 8,000, 16,000, and 24,000) plus a G-tube formulation for patients unable to swallow capsules, supporting individualized dosing across a broad patient population.

Digestive Care operates a sales-led, prescription-based go-to-market in which healthcare providers (gastroenterologists, pulmonologists treating cystic fibrosis, and related specialists) prescribe PERTZYE and patients fill prescriptions through retail and specialty pharmacies. Distribution is US-only, with PERTZYE manufactured in the United States. The company operates between 11 and 50 employees and supports its franchise with an extensive suite of patient access and adherence programs, including a Co-Pay Card, EPI Nutrition Program, First Start Program, Infant Starter Program, My EPI Plan, Pertzye Care, and an Uninsured Patient Assistance Program.

The company remains privately held with no disclosed parent company, institutional investors, or funding rounds. Commercial activity is concentrated entirely on the PERTZYE franchise; no additional pipeline assets, partnerships, acquisitions, or geographic expansion initiatives are identified in the available data. Pricing is not publicly disclosed and is described as determined by insurance coverage, pharmacy benefit managers, and patient assistance programs.

Digestive Care firmographics

Firmographics
Name
Digestive Care
Legal name
Digestive Care, Inc.
Website
https://digestivecare.com
Company type
Private
Founded year
1990
Operating status
Operating
Headcount range
11–50 employees
Short description
Digestive Care is a private US specialty pharmaceutical company that develops and manufactures PERTZYE, the only FDA-approved pancreatic enzyme replacement therapy containing bicarbonate-buffered enteric-coated microspheres, for adult and pediatric patients with exocrine pancreatic insufficiency (EPI).
Ownership category
akta.pro rank

Digestive Care industry classification

Industry
Product category
Prescription Pharmaceuticals
akta.pro industry
PRIMARYHLAIACAE
Gastroenterology Specialty Pharmaceuticals
SECONDARYHLAKAEAG
Pancreaticobiliary Disorders

Keywords

  • Pancreatic enzyme therapy
  • Exocrine pancreatic insufficiency
  • Prescription pharmaceuticals
  • Gastroenterology drugs
  • Cystic fibrosis treatment

Where Digestive Care is headquartered

Location

Headquarters

HQ city
Bethlehem
HQ country
United States
HQ region
North America

Markets served

Digestive Care business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Prescription Pharmaceutical Sales: Digestive Care generates revenue through the sale of prescription pancreatic enzyme replacement therapy (PERT) products. Pertzye is available in multiple dosage strengths (4000, 8000, 16000, and 24000 lipase units) and as a G-tube formulation for patients who cannot swallow capsules.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Digestive Care product offering

Product offering

Core offering

Digestive Care manufactures and markets PERTZYE (pancrelipase), a prescription pancreatic enzyme replacement therapy (PERT) for treating exocrine pancreatic insufficiency (EPI) in adult and pediatric patients. The product line is available in four capsule strengths (4000, 8000, 16000, and 24000 lipase units) plus a G-tube formulation for patients with swallowing difficulties, all built on proprietary Bicarbonate-Buffered Enteric-Coated Microsphere technology.

Product overview

Digestive Care offers a unified portfolio of prescription pancreatic enzyme replacement therapies centered on PERTZYE, the only PERT containing Bicarbonate-Buffered Enteric-Coated Microspheres. The product line consists of five dosage strengths (4000, 8000, 16000, and 24000 lipase units) plus a G-tube formulation, all designed to treat exocrine pancreatic insufficiency (EPI) in adults and children. The various lipase unit strengths allow for individualized dosing based on patient needs, while the G-tube variant addresses administration challenges for patients with swallowing difficulties. The portfolio is supported by patient assistance programs including Co-Pay Card, EPI Nutrition Program, First Start Program, Infant Starter Program, My EPI Plan, Pertzye Care, and Uninsured Patient Assistance Program.

Differentiator

Problem solved

Functional benefit

Brands

  • PERTZYE: Pancreatic Enzyme Replacement Therapy (PERT) containing Bicarbonate-Buffered Enteric-Coated Microspheres, available in 4000, 8000, 16000, and 24000 lipase unit capsules

Products and services

  • PERTZYE 4000 Pancreatic Enzyme Replacement Therapy (PERT) capsules containing 4000 lipase units, indicated for treatment of exocrine pancreatic insufficiency (EPI) in adult and pediatric patients.
  • PERTZYE 8000
  • PERTZYE 16000
  • PERTZYE 24000
  • PERTZYE G-tube

Companies that use Digestive Care

Customer profile

Segments3 records

Ideal customer profiles3 records

Digestive Care technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Digestive Care partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves4 records

Expansion highlights4 records

Digestive Care competitors and assessment

Company assessment

Direct peers

  • Nestlé Health Science: Nestlé Health Science markets Zenpep, one of the leading US PERT products with multiple dosage strengths. Directly competes with PERTZYE in the same pancreatic enzyme replacement category for EPI patients across adult and pediatric populations.
  • Chiesi Farmaceutici: Chiesi was the original developer of the PERTZYE formulation (originally branded PANCRECARB) and markets competing pancreatic enzyme products internationally. Has deep technical familiarity with the bicarbonate-buffered microsphere technology underlying Digestive Care's product.
  • ANI Pharmaceuticals: ANI Pharmaceuticals markets generic and branded pancrelipase products including competing PERT formulations. Directly competes in the same EPI category with similar capsule-based delivery across multiple dosage strengths.
  • AbbVie: AbbVie markets Creon, the market-leading pancreatic enzyme replacement therapy with majority share in the US PERT market. Directly competes with PERTZYE across the same gastroenterology, pulmonology, and pancreatic insufficiency prescriber base.
  • Vivus: Vivus markets Pancreaze, a competing pancreatic enzyme replacement therapy capsule product. Directly competes with PERTZYE across the same EPI prescriber channels with similar capsule-based delivery and multiple dosage strengths.

Broad incumbents

  • Takeda Pharmaceutical: Takeda operates a broad gastroenterology and rare disease portfolio including enzyme and GI therapies. While not a direct US PERT competitor, operates in the same gastroenterology specialty prescriber channel where Digestive Care competes for attention and formulary access.
  • Bausch Health (Salix Pharmaceuticals): Salix Pharmaceuticals is Bausch Health's gastroenterology specialty division with a broad GI product portfolio including pancreatic enzymes (historically Viokace). Operates in the same gastroenterology prescriber channel as Digestive Care with overlapping physician relationships.

Emerging players

  • Alcresta Therapeutics: Alcresta specializes in pancreatic enzyme products for pediatric and tube-fed patients including those with cystic fibrosis. Adjacent PERT competitor focused on specialized delivery formats that overlap with PERTZYE's G-tube and pediatric positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Digestive Care social profiles

Digital presence

Digestive Care financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Digestive Care leadership team

Management profile

Number of profiles

Profiles1 record

Digestive Care funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Digestive Care M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Digestive Care

What does Digestive Care do?

Digestive Care manufactures and markets PERTZYE (pancrelipase), a prescription pancreatic enzyme replacement therapy (PERT) for treating exocrine pancreatic insufficiency (EPI) in adult and pediatric patients. The product line is available in four capsule strengths (4000, 8000, 16000, and 24000 lipase units) plus a G-tube formulation for patients with swallowing difficulties, all built on proprietary Bicarbonate-Buffered Enteric-Coated Microsphere technology.

Is Digestive Care a public or private company?

Digestive Care is a private company. It is classified as unknown and is currently operating.

When was Digestive Care founded?

Digestive Care was founded in 1990. It employs 11 to 50 people.

Where is Digestive Care based?

Digestive Care is headquartered in Bethlehem, United States, in the North America region.

How does Digestive Care make money?

One revenue line is on record: prescription Pharmaceutical Sales.

Who are Digestive Care's main competitors?

Direct peers on record are Nestlé Health Science, Chiesi Farmaceutici, ANI Pharmaceuticals, AbbVie and Vivus. Broad incumbents are Takeda Pharmaceutical and Bausch Health (Salix Pharmaceuticals). Alcresta Therapeutics is listed as an emerging player.

Does Digestive Care have an API?

No public API is recorded for Digestive Care.

What industry is Digestive Care in?

Digestive Care's product category is Prescription Pharmaceuticals. Its primary akta.pro industry code is HLAIACAE, Gastroenterology Specialty Pharmaceuticals, with a secondary code of HLAKAEAG, Pancreaticobiliary Disorders.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireDigestive Care, Inc. Announces FDA Approval of a 24,000 USP Lipase Units Capsule of PERTZYE(R) (pancrelipase) Delayed Release Capsules to Treat Exocrine Pancreatic Insufficiency (EPI) Due to Cystic FiDigestive Care, Inc. and Chiesi announced FDA approval of a 24,000 USP lipase units PERTZYE capsule for exocrine pancreatic insufficiency due to cystic fibrosis. The larger capsule size may reduce the number of capsules needed to reach weight-based doses. The company stated it is committed to offering therapeutic options for this complex condition.GlobeNewswireDigestive Care, Inc. Announces FDA Labeling Revision Approval for PERTZYE(R) (pancrelipase)Digestive Care, Inc. and Chiesi announced FDA approval of a labeling revision for PERTZYE (pancrelipase) to allow gastrostomy tube administration of the 4,000 USP lipase units capsule. The revision enables G-tube use for exocrine pancreatic insufficiency due to cystic fibrosis or other conditions. The company stated this is the first FDA-approved G-tube administration of enteric-coated pancreatic enzyme microspheres.GlobeNewswireDigestive Care, Inc. Donates Year-Long Supply of PERTZYE(R) (Pancrelipase) to Cystic Fibrosis Patients in El SalvadorDigestive Care, Inc. and Cornerstone Therapeutics donated a year's supply of PERTZYE (pancrelipase) to the Benjamin Bloom Children's Hospital in El Salvador on February 11, 2014. The donation addresses exocrine pancreatic insufficiency in cystic fibrosis patients, whose median survival is lower than in the U.S. due to limited access to therapy.